SGY.TO -0.42CJ.TO -0.35GEI.TO -0.79TLN -10.16RITM -0.15UBER -3.81AAAU 1.645MNT.TO 1.18
Eli Lilly & Co. (LLY)

NYSE:LLY

Eli Lilly & Co. (LLY)

1,157.05
+41.37 (3.71%)
as of Aug 5, 2026, 7:16:12 pm Market Open.
220 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 5, 2026, 12:00 am

This summary was created by AI, based on 29 opinions in the last 12 months.

Eli Lilly & Co. (LLY) is positioning itself strongly in the healthcare market, particularly in the GLP-1 drug sector, leading to significant earnings growth expectations of around 25% annually in the coming years. Analysts emphasize LLY's competitive edge over Novo Nordisk (NVO), noting that their innovations have resulted in increased market share, particularly with the anticipated approval of an oral weight-loss pill. Many highlights include a solid pipeline of drugs and an expanding presence in treatment areas such as obesity and diabetes, while recent momentum has seen the stock breaking into new highs. However, there's caution over potential valuations due to the stock’s strong performance and the RSI nearing overbought territory. Overall, LLY is seen as a reliable long-term growth story amid a transformation from a traditional steady income earner to a fast-growing pharmaceutical company.

consensus icon
Consensus
Bullish
valuation icon
Valuation
Overvalued
review icon
Similar
ThermoFisher, TMO
HOLD

Eli Lilly & Co.(LLY)

Mar 15, 2006
Eli Lilly is a good company. It looks fine. It has come down with the other large cap drug stocks in the States. Need to be patient. It offers decent value here.
Photo of Laura WallaceLaura Wallace
No
Unlock Rating
$56.97

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Aug 25, 2005
This is a part of the market that's lagging. There has been such a slowdown in the growth rates.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$53.50

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Jul 13, 2005
Prefers others such as Abbott Labs (ABT-N).
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$56.37

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Eli Lilly & Co.(LLY)

May 03, 2005
Pharmaceutical sector did very poorly over the last 2 years, but deceleration in revenue growth has slowed and profitability has started to improve. Look for the strongest perfoming stock in the sector. As Eli Lilly (LLY-N) is performing better, that would be the better of the 2, but would suggest you look at Sanofi-Aventis (SNY-N) which is close to new highs and Teva Pharmaceuticals (TEVA-Q) in generics.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$59.75

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Mar 15, 2005
A little bit of risk in a 3/6 month view as to whether they can retain their patent on Sprizecta (?), but the longer term they have the best drug pipeline and growth in the sector. OK for a long term hold.
Photo of George LougheryGeorge LougheryUnlock Rating
$52.70

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Eli Lilly & Co.(LLY)

Aug 13, 2004
Lots of new products. Rapid profit growth.
Photo of Samuel D. IsalySamuel D. Isaly
Owned
Unlock Rating
$61.57

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Eli Lilly & Co.(LLY)

Jul 16, 2004
Powerful balance sheet.
Photo of Alan BlakeAlan Blake
Owned
Unlock Rating
$66.30

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Eli Lilly & Co.(LLY)

Apr 16, 2004
Photo of Richard BernstienRichard Bernstien
Owned
Unlock Rating
$72.45

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Apr 02, 2002
Has a very good pipeline. Getting more competition from generic drugs. Too focused on Prozac.
Photo of Joe ConnollyJoe ConnollyUnlock Rating
$78.74

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Dec 10, 2001
Pharmaceuticals may be re-establishing themselves for market leadership. Prefers Lily and Abbot
Photo of David BurrowsDavid BurrowsUnlock Rating
$81.54

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Oct 30, 2001
Some of their drugs are coming off patent and others not doing as well. Prefers Pfizer or J & J.
Photo of Neil MurdockNeil MurdockUnlock Rating
$77.27

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Eli Lilly & Co.(LLY)

Sep 10, 2001
Good pipeline for new drugs but prefers Pfizer.
Photo of Brad WillockBrad WillockUnlock Rating
$77.20

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Jun 05, 2001
Prozac about to go generic.
Photo of Ross HealyRoss HealyUnlock Rating
$88.10

Stock price when the opinion was issued

$1169.86

As of Aug 05, 2026. Market Open.

biotechnologypharmaceutical
Showing 196 to 208 of 208 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

TPZ.TO 0.36$13.75
WCP.TO -0.42$15.85
RGSI.TO 0$
ENB.TO -2.38$72.71
PHX.TO 0.3$11.22
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

SGY.TO -0.42$9.75
CJ.TO -0.35$10.73
GEI.TO -0.79$30.64
TLN -10.16$329.84
RITM -0.15$10.1

Popular Articles

Latest Sell Signals

VET.TO -0.71$14.8
TOU.TO 0.36$13.75
AMD -36.53$482.05
PFE 0.4$25.81
T.TO 0.36$13.75

Most Recent Experts

Jerome Hass

Jerome Hass

Lightwater Partners

Mike Vinokur, CFA, CMT, and CFP

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

The Monthly Gems by Allan Tong

The Monthly Gems by Allan Tong

Stockchase

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like